NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/metagenomi-loss-submission-form/?id=111430&from=3 CLASS PERIOD: This lawsuit is on ...

PHILADELPHIA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Metagenomi Inc. (“Metagenomi” or the “Company”) (NASDAQ: MGX) on behalf of purchasers of Metagenomi securities between February 6, 2024 and September 26, 2024, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired METAGENOMI securities during the Class Period may, no later than NOVEMBER 25, 2024, seek to be appointed as a lead pla ...

NEW YORK, Nov. 09, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Metagenomi, Inc. (NASDAQ: MGX) pursuant and/or traceable to the Company’s initial public offering conducted between February 9 and 13, 2024 (the “IPO”), of the important November 25, 2024 lead plaintiff deadline. SO WHAT: If you purchased Metagenomi stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Metagenomi, Inc. (NASDAQ: MGX) pursuant and/or traceable to the Company’s initial public offering conducted between February 9 and 13, 2024 (the “IPO”), of the important November 25, 2024 lead plaintiff deadline. SO WHAT: If you purchased Metagenomi stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

Core Viewpoint - Metagenomi, Inc. is facing a class action lawsuit following the termination of its collaboration with Moderna, which was a significant aspect of its initial public offering narrative [2]. Group 1: Company Overview - Metagenomi, Inc. is characterized as a "genetic medicines company" and had a strategic collaboration with Moderna, which was highlighted during its initial public offering [2]. - The company completed its IPO on February 13, 2024, selling 6.25 million shares at a price of $15 per share [2]. Group 2: Key Events - On May 1, 2024, Metagenomi announced the mutual termination of its collaboration agreement with Moderna, which was unexpected and raised concerns about the company's future [2]. - Following the announcement, Metagenomi's stock price fell from $7.04 per share on May 1, 2024, to $6.17 per share on May 2, 2024, indicating a significant market reaction to the news [2]. Group 3: Legal Proceedings - A class action lawsuit has been initiated for shareholders who purchased shares during the IPO period from February 9 to 13, 2024, with a deadline for registration set for November 25, 2024 [3]. - Shareholders are encouraged to register for the class action to receive updates and monitor the case's progress [3].

Core Points - A shareholder class action lawsuit has been filed against Metagenomi, Inc. alleging that the company made materially false and misleading statements regarding its collaboration agreement with Moderna, which harmed investors [1] - The lawsuit specifically targets investors who purchased shares of Metagenomi on or after February 13, 2024, and experienced significant losses [2] - The deadline for investors to request to be appointed as lead plaintiff in the case is November 25, 2024 [3]

Core Points - Metagenomi, Inc. (NASDAQ: MGX) is facing a class action lawsuit following the termination of its collaboration with Moderna, which was a significant aspect of its business model [3][4] - The company completed its initial public offering (IPO) on February 13, 2024, selling 6.25 million shares at $15 per share, but the stock price fell from $7.04 to $6.17 within a day after the announcement of the collaboration termination [3] Group 1 - The lawsuit is on behalf of shareholders who purchased stock during the class period from February 9 to 13, 2024, related to Metagenomi's IPO [2][4] - The termination of the collaboration with Moderna was unexpected and raised concerns about Metagenomi's future prospects [3] - The Gross Law Firm is leading the class action, emphasizing its commitment to protecting investors' rights against deceitful practices [5] Group 2 - Shareholders are encouraged to register for the class action by November 25, 2024, to potentially become lead plaintiffs [4] - The firm offers portfolio monitoring software to keep registered shareholders updated on the case's progress [4] - The lawsuit highlights the importance of accurate disclosures and the impact of misleading statements on stock performance [5]

NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Metagenomi, Inc. (“Metagenomi” or the “Company”) (NASDAQ: MGX) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Metagenomi securities pursuant and/or traceable to Metagenomi's registration statement for the initial public of ...

PHILADELPHIA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Metagenomi Inc. (“Metagenomi” or the “Company”) (NASDAQ: MGX) on behalf of purchasers of Metagenomi securities between February 6, 2024 and September 26, 2024, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired METAGENOMI securities during the Class Period may, no later than NOVEMBER 25, 2024, seek to be appointed as a lead pla ...

Group 1 - The lawsuit is on behalf of shareholders who purchased Metagenomi, Inc. (NASDAQ: MGX) shares during the initial public offering (IPO) period from February 9 to 13, 2024 [1] - Metagenomi's IPO involved selling 6.25 million shares at a price of $15 per share, and the company claimed a significant partnership with Moderna, which was a key aspect of its business model [2] - The collaboration with Moderna was terminated on May 1, 2024, leading to a decline in Metagenomi's stock price from $7.04 to $6.17 per share within a day [2] Group 2 - Shareholders are encouraged to register for the class action lawsuit by November 25, 2024, to potentially become lead plaintiffs and receive updates on the case [3] - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements or omissions by companies [4]